摘要
目的 评价中成药清肺胶囊与EP方案 (VP16 +DDP)联合应用在小细胞肺癌治疗中的近期和远期疗效。方法 12 6例小细胞肺癌的患者 ,随机分为单纯化疗组和化疗中药联合治疗组 ,对照组采用标准EP方案 ,联合治疗组用EP方案 +清肺胶囊 ,进行前瞻性对比观察和为期 5年的远期疗效评价。结果 联合治疗组获得 34 4 %的完全缓解率和 89 1%的总有效率 ,对照组分别为 2 4 2 % ,70 3% ,两组差异显著 (P <0 .0 5 ) ;远期疗效 1,2 ,3,5年的生存率联合组分别为 5 4 7% (35 /6 4 ) ,2 9 4 % (15 /5 1) ,19 4 % (7/36 ) ,15 1% (5 /33) ,对照组分别为 4 6 8% (2 9/6 2 ) ,11 4 % (5 /4 4 ) ,5 7% (92 /35 ) ,3 1% (1/32 )。两组比较 ,2 ,3,5年生存率均有统计学意义。 (P <0 .0 5 )。结论 用EP方案联合中药清肺胶囊治疗小细胞肺癌具有较好的耐受性和安全性 ,其近期疗效和远期疗效均优于单纯化疗组 。
Objective To evaluate the therapeutic effect of pulmocathartic capsule combined with etoposide-cisplatin(EP) (VP16+DDP) in the patients with small cell lung cancer(SCLC).Methods A randomized clinical trial was undertaken,comparing EP along to pulmocathartic capsule and EP,126 cases with SCLC were observed, experimental group,used pulmocathartic capsule and EP, controll group used EP along and 5 years term effect was evaluated.Results The complete response rate (CR) and overall response rate (CR+PR) were 34.4% and 89.1% in experimental group,24.2% and 70.3% in controlled group,respectively (P<0.05).The one-year survival rate ,2-year survival rate ,3-year survival rate and 5-year survival rate were 54.7%(35/64),29.4%(15/51),19.4%(7/36) and 15.1%(5/33) in experimental group,respectively;46.8%(29/62),11.4(5/44),5/7%(92/35) and 3.1%(1/32) in controlled group, there's difference in 2、3、5 years survival rate of the two group,P<0.05.Conclusion Pulmocathartic capsule combined with EP in SCLC was more effective than EP along. The traditional Chinese medicine combined with EP was safe and efficient.
出处
《医药论坛杂志》
2004年第15期13-15,共3页
Journal of Medical Forum
关键词
清肺胶囊
小细胞肺癌
化疗
Pulmocathartic capsule
Small cell lung cancer(SCLC)
Chemotherapy
